Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients

Nicole L. Lanza, Allison L. McClellan, Hatim Batawi, Elizabeth Felix, Konstantinos D. Sarantopoulos, Roy C Levitt, Anat Galor

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Purpose To compare dry eye (DE) symptoms and signs in subjects who tested positive versus those who tested negative for ocular surface matrix metalloproteinase 9 (MMP-9) using the InflammaDry point-of-care test (RPS, Sarasota, FL). Methods In this cross-sectional study, individuals seen in the Miami Veterans Affairs eye clinic with DE symptoms, as evidenced by DE questionnaire 5 (DEQ5) ≥6, were given standardized questionnaires to assess DE symptoms and ocular and non-ocular pain complaints. Also, a complete evaluation was conducted to measure ocular surface signs of DE. MMP-9 testing was performed using the InflammaDry once in each eye, per the manufacturer's instructions. The main outcome measure was a comparison of DE symptoms and signs in MMP-9 positive versus negative subjects. Results Of 128 subjects, 50 (39%) were positive for MMP-9 for InflammaDry testing in either eye. No statistically significant differences in mental health indices, DE symptoms, or ocular surface signs were seen in subjects based on MMP-9 status. Conclusion In our population, there was no difference in the DE profile by both symptoms and signs between those testing positive versus negative for MMP-9 on the ocular surface. This suggests that clinical exam alone cannot predict patients with clinically significant inflammation.

Original languageEnglish (US)
Pages (from-to)216-223
Number of pages8
JournalOcular Surface
Volume14
Issue number2
DOIs
StatePublished - Apr 1 2016

    Fingerprint

Keywords

  • dry eye
  • InflammaDry
  • matrix metalloproteinase-9

ASJC Scopus subject areas

  • Ophthalmology

Cite this